This year’s congress of the European Society for Medical Oncology , which took place in Berlin from October 17 to 21, 2025, offered an impressive variety of topics on numerous tumor entities and therapeutic approaches. These were presented in various formats. These included interactive formats such as the “Challenge your Expert” sessions, in which the audience could ask questions, make critical comments and confront the experts with practical challenges. In the “Challenge your Expert-Session-Gynae-Cancers”, David M. Gershenson presented new therapeutic approaches for low-grade serous ovarian cancer (LGSOC). His presentation focused on the development of innovative combination therapies that go beyond the current standards of chemotherapy and hormone therapy and open up new horizons for the treatment of this rare tumor entity.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- BRAF
- Chemotherapy + Letrozole versus Letrozole
- Combination therapy
- Hormonal therapy
- international Phase II/III study GOG 0281
- Johns Hopkins study
- KRAS
- Low grade serous ovarian carcinoma (LGSOC)
- Maintenance therapy
- MAP kinase signaling pathway mutation
- MD Anderson Cancer Center (MDACC)
- Mixed tumors LGSOC and HGSOC
- molecular precision medicine
- NRAS
You May Also Like
- Oncology
Study updates from the ESMO Congress
- High-dose influenza vaccine
Lower hospitalization rates – even with heart failure
- From statins to metformin
Preventive pharmacology and longevity
- Important basics and studies on cancer and the psyche
Interplay between cancer and mental illness
- From symptom to diagnosis
Abdominal pain – angiosarcoma
- Pediatric epilepsy
Diazepam nasal spray for infants
- Findings from research on the generalization of exposure therapy
Treatment of comorbid anxiety
- Symptom-free despite asthma?